PDCD1 and neoplasm: Although high tumor mutational burden (TMB) has recently been reported to correlate with elevated irAEs risk across cancer types (9), large proportion (> 50%) of variation in irAEs risk has not yet been accounted for during anti–PD-1 therapy, indicating the role of other factors in leading to irAEs.